Frytak S - Search Results

1

Recombinant leukocyte A interferon with doxorubicin. A phase I study in advanced solid neoplasms and implications for hepatocellular carcinoma.

Creagan ET, Long HJ, Frytak S, Moertel CG. Creagan ET, et al. Among authors: frytak s. Cancer. 1988 Jan 1;61(1):19-22. doi: 10.1002/1097-0142(19880101)61:1<19::aid-cncr2820610105>3.0.co;2-8. Cancer. 1988. PMID: 2825959

2

Phase II evaluation of menogaril in patients with advanced hypernephroma.

Long HJ, Hauge MD, Therneau TM, Buckner JC, Frytak S, Hahn RG. Long HJ, et al. Among authors: frytak s. Invest New Drugs. 1991 Aug;9(3):261-2. doi: 10.1007/BF00176980. Invest New Drugs. 1991. PMID: 1838363 Clinical Trial.

3

Disseminated malignant melanoma and recombinant interferon: analysis of seven consecutive phase II investigations.

Creagan ET, Schaid DJ, Ahmann DL, Frytak S. Creagan ET, et al. Among authors: frytak s. J Invest Dermatol. 1990 Dec;95(6 Suppl):188S-192S. doi: 10.1111/1523-1747.ep12875512. J Invest Dermatol. 1990. PMID: 2124246 Free article. Clinical Trial.

4

Phase I study of recombinant leukocyte A interferon (IFN-alpha 2A, Roferon-A) with doxorubicin in advanced malignant disease.

Creagan ET, Frytak S, Long HJ, Kvols LK. Creagan ET, et al. Among authors: frytak s. Cancer. 1989 Sep 1;64(5):1034-7. doi: 10.1002/1097-0142(19890901)64:5<1034::aid-cncr2820640512>3.0.co;2-a. Cancer. 1989. PMID: 2474365

5

Treatment toxicities in long-term survivors of limited small cell lung cancer.

Frytak S, Shaw JN, Lee RE, Eagan RT, Shaw EG, Richardson RL, Creagan ET, Coles DT, Jett JR. Frytak S, et al. Cancer Invest. 1988;6(6):669-76. doi: 10.3109/07357908809078033. Cancer Invest. 1988. PMID: 2854492

6

Phase II study of recombinant alfa-2a interferon in patients with advanced bone sarcomas.

Edmonson JH, Long HJ, Frytak S, Smithson WA, Itri LM. Edmonson JH, et al. Among authors: frytak s. Cancer Treat Rep. 1987 Jul-Aug;71(7-8):747-8. Cancer Treat Rep. 1987. PMID: 3038315

7

Phase II study of recombinant gamma-interferon in patients with advanced nonosseous sarcomas.

Edmonson JH, Long HJ, Creagan ET, Frytak S, Sherwin SA, Chang MN. Edmonson JH, et al. Among authors: frytak s. Cancer Treat Rep. 1987 Feb;71(2):211-3. Cancer Treat Rep. 1987. PMID: 3100037 No abstract available.

8

Phase II study of recombinant interferon-gamma in patients with disseminated malignant melanoma.

Creagan ET, Ahmann DL, Long HJ, Frytak S, Sherwin SA, Chang MN. Creagan ET, et al. Among authors: frytak s. Cancer Treat Rep. 1987 Sep;71(9):843-4. Cancer Treat Rep. 1987. PMID: 3113730

9

Recombinant interferons in the management of advanced malignant melanoma. Updated review of five prospective clinical trials and long-term responders.

Creagan ET, Schaid DJ, Ahmann DL, Frytak S. Creagan ET, et al. Among authors: frytak s. Am J Clin Oncol. 1988 Dec;11(6):652-9. doi: 10.1097/00000421-198812000-00013. Am J Clin Oncol. 1988. PMID: 3142248

10

A phase I clinical trial of recombinant human tumor necrosis factor.

Creagan ET, Kovach JS, Moertel CG, Frytak S, Kvols LK. Creagan ET, et al. Among authors: frytak s. Cancer. 1988 Dec 15;62(12):2467-71. doi: 10.1002/1097-0142(19881215)62:12<2467::aid-cncr2820621202>3.0.co;2-5. Cancer. 1988. PMID: 3191449

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

115 results

Search Page

Filters